GlobalData on MSN
AtaCor raises $75m for trial of EV-ICD system
The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.
SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback